68 related articles for article (PubMed ID: 16995417)
1. EVI1 induces myelodysplastic syndrome in mice.
Buonamici S; Li D; Chi Y; Zhao R; Wang X; Brace L; Ni H; Saunthararajah Y; Nucifora G
J Clin Invest; 2004 Sep; 114(5):713-9. PubMed ID: 15343390
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
Yuasa H; Oike Y; Iwama A; Nishikata I; Sugiyama D; Perkins A; Mucenski ML; Suda T; Morishita K
EMBO J; 2005 Jun; 24(11):1976-87. PubMed ID: 15889140
[TBL] [Abstract][Full Text] [Related]
3. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
[TBL] [Abstract][Full Text] [Related]
4. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
[TBL] [Abstract][Full Text] [Related]
5. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
[TBL] [Abstract][Full Text] [Related]
6. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
Tanaka A
Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
[TBL] [Abstract][Full Text] [Related]
7. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.
Boyd KE; Xiao YY; Fan K; Poholek A; Copeland NG; Jenkins NA; Perkins AS
Blood; 2006 Jan; 107(2):733-41. PubMed ID: 16204320
[TBL] [Abstract][Full Text] [Related]
8. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide.
Zhang Y; Sicot G; Cui X; Vogel M; Wuertzer CA; Lezon-Geyda K; Wheeler J; Harki DA; Muzikar KA; Stolper DA; Dervan PB; Perkins AS
Biochemistry; 2011 Dec; 50(48):10431-41. PubMed ID: 22039883
[TBL] [Abstract][Full Text] [Related]
9. EVI1-mediated Programming of Normal and Malignant Hematopoiesis.
Lux S; Milsom MD
Hemasphere; 2023 Oct; 7(10):e959. PubMed ID: 37810550
[No Abstract] [Full Text] [Related]
10. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
Ng HL; Robinson ME; May PC; Innes AJ; Hiemeyer C; Feldhahn N
Br J Haematol; 2024 Mar; 204(3):945-958. PubMed ID: 38296260
[TBL] [Abstract][Full Text] [Related]
11. Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
Menshawy NE; El-Ghonemy MS; Ebrahim MA; Fahmi MW; Saif M; Denewer M; El-Ashwah S
Ann Hematol; 2024 May; ():. PubMed ID: 38710877
[TBL] [Abstract][Full Text] [Related]
12. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
[TBL] [Abstract][Full Text] [Related]
13. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
14. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
15. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.
Vasku A; Vasku JB; Necas M; Vasku V
J Biomed Biotechnol; 2010; 2010():805907. PubMed ID: 20625418
[TBL] [Abstract][Full Text] [Related]
18. [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
Fuchs O
Cas Lek Cesk; 2006; 145(8):619-24. PubMed ID: 16995417
[TBL] [Abstract][Full Text] [Related]
19. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
